Breast Cancer

Latest News
January 17th 2025

FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer

January 15th 2025

BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer

January 13th 2025

Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy

January 9th 2025

Elinzanetant Excels in Phase 3 Study for Vasomotor Symptom Relief

January 8th 2025

Impact of Sexual Counseling on Women With Breast Cancer

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Video Interviews
View All
January 16th 2025

Innovations in Breast Cancer Treatment With Dr Dawn Klemow

December 23rd 2024

Leveraging AI to Reduce Breast Cancer Risk

December 21st 2024

TILs: A Decade of Research Shapes Global Standards for Breast Cancer

December 11th 2024

EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer

November 21st 2024

Targeted Therapies, Genomic Profiling Revolutionize Breast Cancer Treatment

November 11th 2024

Future Breast Cancer Treatments: A Focus on SERDs, Biomarkers

November 6th 2024

Breast Cancer Challenges and Promises in Immunotherapy

October 22nd 2024

Improving Access and Outcomes in HR+/HER2– Breast Cancer Treatment

October 21st 2024

Rise of Innovative Therapies for Breast Cancer Treatment

August 12th 2024

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Podcasts
View All
October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

October 6th 2020

Living Life With Metastatic Breast Cancer From a Male Perspective

More News

Vivek H. Murthy, MD, MBA | Image Credit: © HHS
January 6th 2025

Alcohol and Cancer: Murthy’s Urgent Call

Maggie L. Shaw
Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.
Top 5 Most-Read Breast Cancer Articles of 2024
December 17th 2024

Top 5 Most-Read Breast Cancer Articles of 2024

Cameron Santoro
The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.
Patients with breast cancer | Image Credit: ST.art - stock.adobe.com
December 12th 2024

Race and Immune Microenvironment Impacts on Breast Cancer Outcomes

Cameron Santoro
Breast cancer outcomes are significantly impacted by race and immune responses, particularly among Black patients with triple-negative subtypes, emphasizing the need to understand these disparities and develop more effective treatment strategies.
Breast cancer research. | Image Credit: Chinnapong - stock.adobe.com
December 11th 2024

Elacestrant Shows Real-World Effectiveness in Metastatic Breast Cancers

Cameron Santoro
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.
Patient takes medication. | Image Credit: sitthiphong - stock.adobe.com
November 29th 2024

Elacestrant Shows Significant PFS Benefit in ESR1-Mutated Metastatic Breast Cancer

Cameron Santoro
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
Young woman receiving breast screening | Image Credit: My Ocean studio - stock.adobe.com
November 23rd 2024

Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer

Cameron Santoro
Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.
Health equity text | Image Credit: Andrii - stock.adobe.com
November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro
Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.
Medicare Expansion | Image Credit: wladimir1804- stock.adobe.com
October 24th 2024

Breast Cancer Outcomes Improved in States With Medicaid Expansion

Cameron Santoro
Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
FDA Approved
October 11th 2024

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

Julia Bonavitacola
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.
Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
October 11th 2024

5 Things to Know Before a Breast Screening

Cameron Santoro
Here are 5 key points for pre–breast screening preparation that cover the areas of risk assessment, lifestyle adjustments, understanding screening details, managing anxiety, and open provider communication.
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
October 10th 2024

Advancing Breast Cancer Care With HER2-Targeted Therapies

Maggie L. Shaw
In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.
Breastcancergeneticrisk | Image Credit: © Rasi-stock.adobe.com
October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Maggie L. Shaw
Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Breast cancer support group | Image Credit: Atstock Productions - stock.adobe.com
October 1st 2024

ACS 2024 Report Shows Breast Cancer Equity Gap

Cameron Santoro
The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.
Breast ultrasound | Image Credit: Василь Івасюк - stock.adobe.com
September 23rd 2024

Celebrating World Dense Breast Day: Raising Awareness and Advocacy of Dense Breasts

Cameron Santoro
World Dense Breast Day emphasizes the need for awareness and advocacy for individuals with dense breasts, which can negatively impact mammogram results and increase breast cancer risk.
FDA approval. | Image Credit: Tada Images - stock.adobe.com
September 17th 2024

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

Cameron Santoro
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer.
Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer
September 13th 2024

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer

Alana Hippensteele
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
Mammogram screening. | Image Credit: Gorodenkoff - stock.adobe.com
September 10th 2024

Breast Density Disclosure Now Mandated for Mammograms

Cameron Santoro
Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.
Health care costs and fees. | Image Credit: Nuttapong punna - stock.adobe.com
September 5th 2024

AI-Enhanced Breast Cancer Screening Economically Viable in the UK

Cameron Santoro
Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.
Demetria Smith-Graziani, MD
August 29th 2024

Narrowing the Focus to Address Care Disparities: Dr Demetria Smith-Graziani

Rose McNulty
While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.
Global breast cancer map. | Image Credit: vectorfusionart - stock.adobe.com
August 21st 2024

Systemic Inequities in Global Breast Cancer Care

Cameron Santoro
A new review highlights the urgent need for research-driven solutions in breast cancer to enhance early detection, treatment, and patient support across diverse populations.
AJMC Q&A With Demetria Smith-Graziani, MD, MPH | Photo credit: Emory Winship Cancer Institute
August 19th 2024

Biological and Structural Factors Fuel Racial Disparities in Breast Cancer

Rose McNulty
Demetria Smith-Graziani, MD, MPH, Emory University School of Medicine, explained biological and structural obstacles to equitable breast cancer outcomes and care across racial and ethnic groups.
Researchers collaborate. | Image Credit: wichayada - stock.adobe.com
August 13th 2024

AI Improves Breast Cancer Detection but Requires Careful Monitoring

Cameron Santoro
Artificial intelligence (AI) can aid in breast cancer detection, but radiologists need training to ensure accuracy and prevent missed cancers.
Harold "Hal" J Burstein, MD, PhD.
August 9th 2024

Navigating Breast Cancer Treatment Through Shared Decision-Making

Cameron Santoro
Harold "Hal" Burstein, MD, PhD, emphasizes the crucial role of strong patient-physician partnerships in breast cancer treatment, empowering patients through shared decision-making.
Medical mammogram exam | Image Credit: TeraVector - stock.adobe.com
August 6th 2024

COVID-19 Disrupted Breast Cancer Screenings, Exacerbated Disparities

Cameron Santoro
The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.
A panel of 4 experts on breast cancer
August 5th 2024

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
A panel of 4 experts on breast cancer
August 5th 2024

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Pink ribbon for breast cancer. | Image Credit: Andrey Popov - stock.adobe.com
July 31st 2024

Black Women With Obesity, Elevated Leptin Levels at Higher Risk for Breast Cancer

Cameron Santoro
The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.
A panel of 4 experts on breast cancer
July 29th 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
A panel of 4 experts on breast cancer
July 29th 2024

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
A panel of 4 experts on breast cancer
July 29th 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A medical expert navigates toxicity management in patients being treated with ribociclib.
12345678
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo